Susceptible-infectious-recovered-susceptible (SIRS) epidemic models assume that individual immunity wanes in one leap, from complete immunity to complete susceptibility. For many diseases immunity on the contrary wanes gradually, something that has become even more evident during COVID-19 pandemic where also recently infected have a reinfection risk, and booster vaccines are given to increase immunity. Here, a novel mathematical model is presented allowing for the gradual decay of immunity following linear or exponential waning functions. The two new models and the SIRS model are compared assuming all three models have the same cumulative immunity. When no intervention is put in place, we find that the long-term prevalence is higher for the models with gradual waning. If aiming for herd immunity by continuous vaccination, it is shown that larger vaccine quantities are required when immunity wanes gradually compared with results obtained from the SIRS model, and this difference is the biggest for the most realistic assumption of exponentially waning of immunity. For parameter choices fitting to COVID-19, the critical amount of vaccine supply is about 50% higher if immunity wanes linearly, and more than 150% higher when immunity wanes exponentially, when compared with the classic SIRS epidemic model.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10498349 | PMC |
http://dx.doi.org/10.1098/rsif.2023.0042 | DOI Listing |
Vaccine
January 2025
Pediatric Infectious Disease Research Center, Tehran University of Medical Sciences, Tehran, Iran; Department of Infectious Diseases, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran. Electronic address:
Introduction: The prevalence of anti-pertussis antibodies among infants and children in Iran has not been thoroughly investigated. Given that recommendations for booster vaccines are based on national disease epidemiology, we aimed to evaluate the seroprevalence of pertussis antibodies among infants and children in an Iranian referral hospital.
Materials And Methods: A total of 1012 infants and children were included in the study.
Narra J
December 2024
Medical Research Unit, School of Medicine, Universitas Syiah Kuala, Banda Aceh, Indonesia.
The waning immunity following the COVID-19 vaccination become a significant concern and the immunological dynamics of vaccine-induced antibodies after vaccination need to be explored. The aim of this study was to compare anti-SARS-CoV-2 receptor-binding domain (RBD) antibody levels before and after a booster dose with heterologous COVID-19 vaccine and to identify factors influencing the levels after receiving the booster dose. A cross-sectional study was conducted in which individuals who received primary doses of CoronaVac and a booster dose with an mRNA-based vaccine were recruited using a purposive sampling technique.
View Article and Find Full Text PDFJ Med Virol
January 2025
Department of Rheumatology and Immunology, The Affiliated Suqian First People's Hospital of Nanjing Medical University, Suqian, Jiangsu, China.
Varicella, a highly contagious disease caused by the varicella-zoster virus (VZV), remains prevalent in China despite the introduction of the varicella vaccine in 1997. The current vaccination protocol in China involves a voluntary, self-funded single-dose regimen. This study aims to investigate the longevity of immune response in Chinese children following two-dose varicella vaccination administered at different intervals, with the objective of optimizing vaccination strategies.
View Article and Find Full Text PDFJ R Soc Interface
January 2025
Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA.
Influenza forecasts could aid public health response as shown for temperate regions, but such efforts are more challenging in the tropics and subtropics due to more irregular influenza activities. Here, we built six forecast approaches for influenza in the (sub)tropics, with six model forms designed to model seasonal infection risk (i.e.
View Article and Find Full Text PDFVaccine
January 2025
Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN 55905, USA. Electronic address:
The mpox virus (MPXV) came to global attention with the 2022 global outbreak. Current vaccination and post-exposure prophylaxis against MPXV consists of live vaccinia whole virus-based vaccines including ACAM2000®, JYNNEOS™, and LC16m8 originally developed against smallpox. Here, we analyzed 152 vaccinia-derived peptides we identified by mass spectrometry for homology with MPXV-1 and MPXV-2 sequences to evaluate their potential relevance to MPXV-specific immunity.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!